# Indivior Pharmaceuticals, Inc.: overview

INDV · Nasdaq · CIK 1625297 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/indv.md) · [Financials](/companies/indv/financials.md) · [Filings](/companies/indv/filings.md) · [Insiders](/companies/indv/insiders.md)

Latest reported revenue: [$356.0m](/filings/0001628280-26-068013.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-068013).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [299 d](/filings/0001628280-26-012237.md) | [266](/filings/0001628280-26-028850.md) | [302](/filings/0001628280-26-051895.md) | [314](/filings/0001628280-26-068013.md) | [358 d](/filings/0001628280-26-012237.md) | [317](/filings/0001628280-26-028850.md) | [343](/filings/0001628280-26-051895.md) | [356](/filings/0001628280-26-068013.md) |
| Gross margin | % | [83.6% d](/filings/0001628280-26-012237.md) | [83.1%](/filings/0001628280-26-028850.md) | [82.8%](/filings/0001628280-26-051895.md) | [73.2%](/filings/0001628280-26-068013.md) | [81.6% d](/filings/0001628280-26-012237.md) | [87.4%](/filings/0001628280-26-028850.md) | [85.7%](/filings/0001628280-26-051895.md) | [85.7%](/filings/0001628280-26-068013.md) |
| Operating margin | % | [15.4% d](/filings/0001628280-26-012237.md) | [24.8%](/filings/0001628280-26-028850.md) | [23.8%](/filings/0001628280-26-051895.md) | [13.7%](/filings/0001628280-26-068013.md) | [22.6% d](/filings/0001628280-26-012237.md) | [43.2%](/filings/0001628280-26-028850.md) | [46.6%](/filings/0001628280-26-051895.md) | [50.6%](/filings/0001628280-26-068013.md) |
| Net margin | % | [7.0% d](/filings/0001628280-26-012237.md) | [17.7%](/filings/0001628280-26-068013.md) | [6.0%](/filings/0001628280-26-068013.md) | [13.4%](/filings/0001628280-26-068013.md) | [28.5% d](/filings/0001628280-26-012237.md) | [28.1%](/filings/0001628280-26-068013.md) | [35.6%](/filings/0001628280-26-068013.md) | [38.5%](/filings/0001628280-26-068013.md) |
| Diluted EPS | $ per share | not reported | [0.38](/filings/0001628280-26-028850.md) | [0.14](/filings/0001628280-26-051895.md) | [0.33](/filings/0001628280-26-068013.md) | not reported | [0.69](/filings/0001628280-26-028850.md) | [0.98](/filings/0001628280-26-051895.md) | [1.12](/filings/0001628280-26-068013.md) |
| Free cash flow | $m | [(33.0) d](/filings/0001628280-26-012237.md) | [70.0](/filings/0001628280-26-028850.md) | [141 d](/filings/0001628280-26-051895.md) | [(59.0) d](/filings/0001628280-26-068013.md) | [(245) d](/filings/0001628280-26-012237.md) | [(29.0)](/filings/0001628280-26-028850.md) | [222 d](/filings/0001628280-26-051895.md) | [83.0 d](/filings/0001628280-26-068013.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY (2021-12-31) | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [791](/filings/0001625297-24-000017.md) | [901](/filings/0001625297-25-000016.md) | [1,093](/filings/0001628280-26-012237.md) | [1,188](/filings/0001628280-26-012237.md) | [1,239](/filings/0001628280-26-012237.md) |
| Gross margin | % | [83.9%](/filings/0001625297-24-000017.md) | [83.1%](/filings/0001625297-25-000016.md) | [84.1%](/filings/0001628280-26-012237.md) | [80.6%](/filings/0001628280-26-012237.md) | [80.2%](/filings/0001628280-26-012237.md) |
| Operating margin | % | [26.9%](/filings/0001625297-24-000017.md) | [(8.5%)](/filings/0001628280-25-047530.md) | [(13.9%)](/filings/0001628280-26-012237.md) | [3.2%](/filings/0001628280-26-012237.md) | [21.1%](/filings/0001628280-26-012237.md) |
| Net margin | % | [25.9%](/filings/0001625297-24-000017.md) | [(4.7%)](/filings/0001628280-25-047530.md) | [(11.5%)](/filings/0001628280-26-012237.md) | [0.6%](/filings/0001628280-26-012237.md) | [16.9%](/filings/0001628280-26-012237.md) |
| Diluted EPS | $ per share | not reported | [(0.30)](/filings/0001628280-25-047530.md) | [(0.92)](/filings/0001628280-26-012237.md) | [0.05](/filings/0001628280-26-012237.md) | [1.64](/filings/0001628280-26-012237.md) |
| Free cash flow | $m | [349](/filings/0001625297-24-000017.md) | [(9.0)](/filings/0001628280-25-047530.md) | [(308)](/filings/0001628280-26-012237.md) | [7.0](/filings/0001628280-26-012237.md) | [(93.0)](/filings/0001628280-26-012237.md) |

- Revenue. XBRL Revenue: ifrs-full:RevenueFromContractsWithCustomers; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:RevenueFromContractsWithCustomers; Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:RevenueFromContractsWithCustomers; Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:RevenueFromContractsWithCustomers; Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/indv/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $767.6m | 18,709,432 |  | Added +167,212 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $310.7m | 7,572,287 |  | Reduced −319,532 |
| [OAKTREE CAPITAL MANAGEMENT LP](/funds/949509.md) | 2026-06-30 | $251.4m | 6,127,212 |  | Reduced −856,890 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $225.5m | 5,495,486 |  | Reduced −91,090 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $204.8m | 4,992,071 |  | Added +88,078 |
| [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $189.4m | 4,615,816 |  | Added +86,233 |
| [Two Seas Capital LP](/funds/1823138.md) | 2026-06-30 | $142.8m | 3,479,493 |  | Reduced −1,267,017 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $139.3m | 3,395,702 |  | Reduced −110,115 |
| [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $136.1m | 3,316,358 |  | Added +3,204,765 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $129.7m | 3,159,866 |  | Added +234,178 |

## Recent filings

[All 544 filings](/companies/indv/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 08:14 ET | [10-Q](/filings/0001628280-26-068013.md) | Quarterly report, period 2026-09-30 | 0001628280-26-068013 |
| 2026-10-29 | 07:00 ET | [8-K](/filings/0001193125-26-436953.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-436953 |
| 2026-10-15 | 16:17 ET | [8-K](/filings/0001104659-26-116253.md) | 5.07 Shareholder vote results | 0001104659-26-116253 |
| 2026-10-06 | 07:15 ET | [8-K](/filings/0001104659-26-113883.md) | 8.01 Other events | 0001104659-26-113883 |
| 2026-09-17 | 07:18 ET | [8-K](/filings/0001104659-26-108417.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-108417 |
| 2026-09-15 | 16:28 ET | [8-K](/filings/0001625297-26-000028.md) | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001625297-26-000028 |
| 2026-08-13 | 17:30 ET | [SCHEDULE 13D/A](/filings/0001140361-26-032874.md) | Ownership report, active investor, amended | 0001140361-26-032874 |
| 2026-08-03 | 16:24 ET | [10-Q](/filings/0001628280-26-051895.md) | Quarterly report, period 2026-06-30 | 0001628280-26-051895 |
| 2026-08-03 | 08:32 ET | [8-K](/filings/0001193125-26-329618.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-329618 |
| 2026-08-03 | 06:50 ET | [8-K](/filings/0001193125-26-329520.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-329520 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-012237.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/9feb26f2-adc4-4e7a-b390-f8464b89b46b)

## About the filer

- CIK: 1625297
- Tickers: INDV
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 08:21 ET. No prices; not investment advice.